Background: Atraumatic splenic rupture is a rare complication of anti-coagulant and anti-platelet therapy in myocardial infarction (MI). We present the case of a 61 yr old female with late presentation (day 5) of inferolateral ST elevation MI. Initial management included ticagrelor, aspirin and weight adjusted enoxaparin without thrombolysis due to delayed presentation. After 4 days, profound hypotension with abdominal discomfort developed. A CT abdomen demonstrated a splenic haematoma with arterial contrast extravasation. Percutaneous splenic artery coiling and embolisation failed to arrest the bleeding, leading to laparotomy and splenectomy. This prompted a literature review of the association between MI and splenic rupture.
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Method: A PubMed and Embase literature review was performed, using the terms "splenic rupture", "spleen", "haemorrhage" and "myocardial infarction" or "acute coronary syndrome". All publications from 1980 onwards with an English language abstract were manually reviewed.
Results and Conclusion: 11 cases of atraumatic splenic rupture in patients with MI in the preceding 3 months were identified. 10 patients had a histologically normal spleen (1-11). 1 patient was subsequently diagnosed with polycythaemia vera. 8 cases were associated with thrombolysis. Inflammatory cytokine release from ischaemic myocardium causes immune cell recruitment and activation of a splenic reservoir of myeloid lineage cells (12, 13) . Iatrogenic activation of similar pathways with high dose G-CSF has also been linked to splenic rupture (14). Atraumatic splenic rupture has been rarely reported post myocardial infarction, often but not exclusively associated with thrombolytic therapy. Background: Fenofibrate increases renal clearance of uric acid (UA). Relationships between baseline and short-term changes in plasma UA with fenofibrate and subsequent cardiovascular risk in patients with type 2 diabetes (T2D) are unknown.
Method: Post hoc analyses of the FIELD trial explored the relationships between CVD events and (1) baseline UA level; and (2) short-term change in UA level over 6-week singleblind active fenofibrate run-in.
Results: Data were from 9,622 patients with T2D. The FIELD trial showed 11% fewer cardiovascular events in patients with T2D assigned to fenofibrate compared to placebo over 5 years (HR = 0.89, 95% CI: 0.80-0.99, p = 0.035). Baseline UA ranged between 0.11 to 0.79 mmol/L (mean = 0.33, SD = 0.078). Each 0.1 mmol/L higher baseline UA increased CVD events by 21% (HR = 1.21 95% CI: 1.13-1.29, p < 0.001; Fig. 1A) , and remained after adjusting for metabolic syndrome and other classic risk factors (HR = 1.12, 95% CI: 1.04-1.21, p = 0.002). Fall in UA level with fenofibrate run-in also predicted lower CVD risk, adjusted for baseline UA and irrespective of long-term treatment allocation (HR = 0.86, 95% CI: 0.76-0.97, p = 0.015; Fig. 1B) .
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reduction in total CVD events with fenofibrate was not shown to be mediated through the lowering of UA levels. 
